X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1696) 1696
Publication (121) 121
Book Review (57) 57
Book Chapter (8) 8
Magazine Article (5) 5
Conference Proceeding (4) 4
Data Set (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
natalizumab (1488) 1488
humans (1461) 1461
index medicus (1065) 1065
multiple sclerosis (916) 916
clinical neurology (718) 718
female (709) 709
male (611) 611
adult (602) 602
multiple sclerosis - drug therapy (597) 597
antibodies, monoclonal - therapeutic use (491) 491
progressive multifocal leukoencephalopathy (480) 480
antibodies, monoclonal, humanized - therapeutic use (427) 427
middle aged (423) 423
antibodies, monoclonal, humanized (420) 420
multiple sclerosis, relapsing-remitting - drug therapy (388) 388
neurosciences (378) 378
immunologic factors - therapeutic use (357) 357
treatment outcome (328) 328
immunosuppressive agents - therapeutic use (304) 304
neurology (284) 284
natalizumab - therapeutic use (268) 268
magnetic resonance imaging (254) 254
placebo-controlled trial (245) 245
therapy (222) 222
antibodies, monoclonal - adverse effects (204) 204
glatiramer acetate (203) 203
drug therapy (198) 198
multiple-sclerosis (184) 184
care and treatment (181) 181
young adult (181) 181
double-blind (171) 171
pharmacology & pharmacy (169) 169
immunology (165) 165
interferon-beta - therapeutic use (160) 160
animals (157) 157
multiple sclerosis - immunology (156) 156
fingolimod (155) 155
leukoencephalopathy, progressive multifocal - chemically induced (152) 152
disease (143) 143
risk factors (142) 142
antibodies, monoclonal, humanized - adverse effects (141) 141
research (136) 136
abridged index medicus (135) 135
patients (135) 135
risk (134) 134
jc virus (133) 133
disease progression (128) 128
recurrence (127) 127
adolescent (122) 122
crohn's disease (122) 122
interferon beta-1a (120) 120
crohn disease - drug therapy (118) 118
disability evaluation (114) 114
interferon (114) 114
monoclonal antibodies (113) 113
follow-up studies (110) 110
medicine, general & internal (110) 110
retrospective studies (110) 110
medicine & public health (108) 108
immunologic factors - adverse effects (107) 107
brain - pathology (106) 106
health aspects (106) 106
disability (102) 102
immunosuppressive agents - adverse effects (102) 102
infliximab (102) 102
psychiatry (102) 102
alemtuzumab (101) 101
aged (100) 100
natalizumab - adverse effects (100) 100
gastroenterology & hepatology (91) 91
multiple sclerosis - pathology (91) 91
multiple sclerosis - therapy (91) 91
efficacy (90) 90
clinical trials (89) 89
relapsing multiple-sclerosis (89) 89
antibodies (88) 88
multiple sclerosis - diagnosis (88) 88
interferon-beta (87) 87
diagnosis (85) 85
rituximab (85) 85
time factors (85) 85
peptides - therapeutic use (84) 84
clinical trials as topic (82) 82
prospective studies (81) 81
leukoencephalopathy, progressive multifocal - diagnosis (80) 80
oral fingolimod (80) 80
medicine (79) 79
multicenter (79) 79
disease-activity (78) 78
multiple sclerosis - complications (78) 78
cerebrospinal-fluid (77) 77
development and progression (77) 77
lymphocytes (77) 77
controlled trial (76) 76
jc virus - immunology (75) 75
fingolimod hydrochloride - therapeutic use (74) 74
analysis (73) 73
fingolimod hydrochloride (70) 70
sphingosine - analogs & derivatives (70) 70
inflammatory-bowel-disease (69) 69
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1586) 1586
German (33) 33
French (26) 26
Spanish (18) 18
Japanese (11) 11
Hungarian (9) 9
Russian (6) 6
Norwegian (5) 5
Danish (3) 3
Dutch (2) 2
Finnish (2) 2
Polish (2) 2
Chinese (1) 1
Czech (1) 1
Icelandic (1) 1
Italian (1) 1
Portuguese (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


INTERNATIONAL IMMUNOLOGY, ISSN 0953-8178, 01/2015, Volume 27, Issue 1, pp. 47 - 53
Multiple sclerosis (MS) is a disorder of putative autoimmune origin, where immune cells invade the central nervous system and cause damage by attacking the... 
EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | risk stratification | CROHNS-DISEASE | progressive multifocal leukoencephalopathy | PML RISK | CENTRAL-NERVOUS-SYSTEM | PLACEBO-CONTROLLED TRIAL | IMMUNOLOGY | natalizumab | T-CELLS | JC VIRUS-ANTIBODIES
Journal Article
The American Journal of Gastroenterology, ISSN 0002-9270, 02/2011, Volume 106, Issue 2, pp. 199 - 212
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 8, pp. 711 - 721
Journal Article
Journal Article
Journal Article